BOSTON, March 31, 2015 - PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today introduced the latest version of its Regulatory Information Management (RIM) platform: LIQUENT InSight® 6.0. The LIQUENT InSight platform supports the entire regulatory product lifecycle, from early planning of registration targets through product retirement, with robust submission planning, publishing, viewing and registration management capabilities.
While biopharmaceutical companies and the patients who can benefit from new drugs are located throughout the world, there is no single international regulatory body to review and approve new medicine applications. For new and innovative medicines to successfully reach patients and maintain regulatory compliance throughout the product lifecycle, biopharmaceutical companies must navigate the complex, global regulatory and region-specific regulations.
“LIQUENT InSight 6.0 simplifies navigation of the global regulatory environment and provides the submission and registration management tools needed to more quickly bring treatments to market and effectively maintain them throughout their lifespan,” said Xavier Flinois, President, PAREXEL Informatics. “As an essential part of the drug development journey, the LIQUENT InSight platform centralizes a company’s regulatory information to drive standardization, improve collaboration, and helps to ensure compliance, eliminate waste, reduce costs, and increase efficiencies so more patients can quickly and safely receive the treatments they need.”
Enhancements to the LIQUENT InSight platform include:
Since the market introduction of LIQUENT InSight in 2004, more than 40 companies (including 14 of the top 20 pharmaceutical companies) have selected the LIQUENT InSight platform as their single source of regulatory information. PAREXEL’s RIM technologies can also be coupled with comprehensive professional services from PAREXEL® Consulting, which provides a full complement of Regulatory Outsourcing Services to help companies meet the demands of today’s complex and changing regulatory environment. LIQUENT InSight 6.0 will also be available through the Perceptive® Partner Program.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.